These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26808357)

  • 41. Longitudinal assessment of a P-glycoprotein-mediated drug interaction of valspodar on digoxin.
    Kovarik JM; Rigaudy L; Guerret M; Gerbeau C; Rost KL
    Clin Pharmacol Ther; 1999 Oct; 66(4):391-400. PubMed ID: 10546923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans.
    Drescher S; Glaeser H; Mürdter T; Hitzl M; Eichelbaum M; Fromm MF
    Clin Pharmacol Ther; 2003 Mar; 73(3):223-31. PubMed ID: 12621387
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lack of interaction between pantoprazole and digoxin at therapeutic doses in man.
    Hartmann M; Huber R; Bliesath H; Steinijans VW; Koch HJ; Wurst W; Kunz K
    Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S67-71. PubMed ID: 8793605
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetic and pharmacodynamic aspects of concomitant mibefradil-digoxin therapy at therapeutic doses.
    Peters J; Welker HA; Bullingham R
    Eur J Drug Metab Pharmacokinet; 1999; 24(2):133-40. PubMed ID: 10510740
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impairment of absorption of digoxin by acarbose.
    Miura T; Ueno K; Tanaka K; Sugiura Y; Mizutani M; Takatsu F; Takano Y; Shibakawa M
    J Clin Pharmacol; 1998 Jul; 38(7):654-7. PubMed ID: 9702852
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib.
    Schwartz JI; Agrawal NG; Wehling M; Musser BJ; Gumbs CP; Michiels N; De Smet M; Wagner JA
    Br J Clin Pharmacol; 2008 Dec; 66(6):811-7. PubMed ID: 18823299
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic and pharmacodynamic drug-drug interaction assessment between pradigastat and digoxin or warfarin.
    Yan JH; Meyers D; Lee Z; Danis K; Neelakantham S; Majumdar T; Rebello S; Sunkara G; Chen J
    J Clin Pharmacol; 2014 Jul; 54(7):800-8. PubMed ID: 24619917
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictive performance of four pharmacokinetic methods for calculating digoxin dosage.
    el-Sayed YM
    J Clin Pharm Ther; 1995 Oct; 20(5):297-304. PubMed ID: 8576297
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.
    Neuhoff S; Yeo KR; Barter Z; Jamei M; Turner DB; Rostami-Hodjegan A
    J Pharm Sci; 2013 Sep; 102(9):3161-73. PubMed ID: 23686764
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males.
    Gerloff T; Schaefer M; Johne A; Oselin K; Meisel C; Cascorbi I; Roots I
    Br J Clin Pharmacol; 2002 Dec; 54(6):610-6. PubMed ID: 12492608
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide.
    Malm-Erjefält M; Ekblom M; Vouis J; Zdravkovic M; Lennernäs H
    Mol Pharm; 2015 Nov; 12(11):4166-73. PubMed ID: 26426736
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population pharmacokinetic investigation of digoxin in Japanese neonates.
    Yukawa E; Akiyama K; Suematsu F; Yukawa M; Minemoto M
    J Clin Pharm Ther; 2007 Aug; 32(4):381-6. PubMed ID: 17635340
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population-based investigation of relative clearance of digoxin in Japanese patients by multiple trough screen analysis: an update.
    Yukawa E; Honda T; Ohdo S; Higuchi S; Aoyama T
    J Clin Pharmacol; 1997 Feb; 37(2):92-100. PubMed ID: 9055134
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Digoxin].
    Yamamoto K
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():403-5. PubMed ID: 15658349
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.
    Chiney MS; Menon RM; Bueno OF; Tong B; Salem AH
    Xenobiotica; 2018 Sep; 48(9):904-910. PubMed ID: 29027832
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Digoxin: clinical highlights: a review of digoxin and its use in contemporary medicine.
    Ehle M; Patel C; Giugliano RP
    Crit Pathw Cardiol; 2011 Jun; 10(2):93-8. PubMed ID: 21988950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Limited sampling strategies to predict the area under the concentration-time curve for rifampicin.
    Medellín-Garibay SE; Correa-López T; Romero-Méndez C; Milán-Segovia RC; Romano-Moreno S
    Ther Drug Monit; 2014 Dec; 36(6):746-51. PubMed ID: 24784025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diagnostic accuracy of a hyperbolic model in predicting digoxin concentrations based on glomerular filtration rates.
    González-López J; Tutor JC
    Nefrologia; 2011; 31(5):573-8. PubMed ID: 21959724
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
    Choi Y; Han H; Shin D; Lim KS; Yu KS
    Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of lapatinib on oral digoxin absorption in patients.
    Koch KM; Smith DA; Botbyl J; Arya N; Briley LP; Cartee L; White JH; Beyer J; Dar MM; Chung HC; Chu Q; Bang YJ
    Clin Pharmacol Drug Dev; 2015 Nov; 4(6):449-53. PubMed ID: 27137717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.